It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting about the safety of a product.
A drug-coated balloon for lower leg angioplasty offered long-lasting relief to patients who had pain when walking, but outside investigators had questions about whether the device increased patient mortality, Mauri told DeviceTalks Editorial Director Tom Salemi in a new interview.
“This created kind of a firestorm,” she said. “I had experienced firestorms like that in the past and other subject areas and been r…